作者：王晓雪，孙维，宁亚媛，陈丽娟

单位：

130041 吉林省长春市，吉林大学第二医院心血管内科通信作者：陈丽娟，E-mail：373800278@qq.com

单位（英文）：

Department of Cardiovascular Medicine，the Second Hospital of Jilin University，Changchun 130041，ChinaCorresponding author：CHEN Lijuan，E-mail：373800278@qq.com

关键词：

心力衰竭；沙库巴曲缬沙坦；血管紧张素受体抑制剂；脑啡肽酶；综述

关键词（英文）：

Heart failure；Sacubitril/Valsartan；Angiotensin receptor antagonists；Neprilysin；Review

中图分类号：

R 541.6

DOI：

10.3969/j.issn.1008-5971.2020.01.002

基金项目：

摘要：

近年来，临床心力衰竭诊断率逐年提高，但心力衰竭患者 5 年生存率改善效果有限。沙库巴曲缬沙坦作为目前世界上唯一在临床应用的血管紧张素受体脑啡肽酶抑制剂，能有效降低多种原因引起的心力衰竭患者再住院率及心血管死亡风险，目前其已被国内外众多临床指南列为Ⅰ类推荐。本文主要综述了沙库巴曲缬沙坦治疗心力衰竭及心力衰竭合并其他常见疾病的研究进展，以期为临床合理应用该药提供参考。

英文摘要：

Clinical diagnosis rate of heart failure increased year by year in recent years，however five-year survivalrate in patients with heart failure improved finitely. Sacubitril/Valsartan，as the only angiotensin receptor neprilysin inhibitor thatapplied on clinic all over the world，can effectively reduce the re-hospitalization rate and cardiovascular death risk in patientswith heart failure that caused by various reasons，moreover it has been classified as Ⅰ -class recommendation by numerousclinical guidelines at home and abroad so far. This paper mainly reviewed the research progress about Sacubitril/Valsartan intreating heart failure and even heart failure merged with other common diseases，in order to provide a reference for its rationalclinical use.

参考文献：